Revance Therapeutics, Inc.
NASDAQ:RVNC
Overview | Financials
Company Name | Revance Therapeutics, Inc. |
Symbol | RVNC |
Currency | USD |
Price | 3.06 |
Market Cap | 319,433,400 |
Dividend Yield | 0% |
52-week-range | 2.3 - 9.745 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mark J. Foley |
Website | https://www.revance.com |
An error occurred while fetching data.
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD